Drug Profile
Complement C1 inhibitor protein - CSL Behring
Alternative Names: Berinert; Berinert HS; Berinert P; C1 esterase inhibitor - CSL Behring; C1 esterase inhibitor concentrate; C1-INH - CSL Behring; C1-inhibitor - CSL Behring; CE 1145; Complement C1 inactivator - CSL Behring; CSL 830; CSL 842; Haegarda; Human C1 esterase inhibitor concentrateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator CSL Behring
- Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Complement C1 inhibitor protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
- No development reported Unspecified
- Discontinued Reperfusion injury; Septic shock; Transplant rejection; Vascular disorders
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Unspecified in USA
- 26 Sep 2022 Launched for Hereditary angioedema (In adolescents, Prevention, In adults) in Japan (SC)
- 26 Sep 2022 Registered for Hereditary angioedema (In adolescents, Prevention, In adults) in Japan (SC)